(Pancreatic Cancer) Is Niraparib + Ipilimumab Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
On July 7, 2022, Kim A. Reiss et al. from Abramson Cancer Center published in the medical journal The Lancet Oncology the "Efficacy and Safety Results of Niraparib + Opdivo and Niraparib + Ipilimumab as Maintenance Therapy in Pancreatic Cancer Patients Who Had Not Progressed After at Least 16 Weeks of Platinum-Based Chemotherapy, from a Phase 1b/2 Clinical Trial."
This Phase 1b/2 clinical trial randomized pancreatic cancer patients who had received platinum-based chemotherapy for at least 16 weeks without disease progression (N=91) in a 1:1 ratio to: the Niraparib (200 mg once daily) + Opdivo (240 mg every two weeks, later changed to 480 mg every four weeks) group (N=46) or the Niraparib (200 mg once daily) + Ipilimumab (3 mg/kg every two weeks) group (N=45). The primary endpoints were safety and 6-month progression-free survival rate.
At a median follow-up of 23.0 months, the primary endpoint 6-month progression-free survival rates were: Niraparib + Opdivo group 20.6% / Niraparib + Ipilimumab group 59.6%.
In terms of safety, Grade 3 or higher adverse event rates were: Niraparib + Opdivo group 22% (N=10/46) / Niraparib + Ipilimumab group (N=23/45). Adverse events in the Niraparib + Opdivo group included hypertension 8%, anemia 4%, and thrombocytopenia 4%. In the Niraparib + Ipilimumab group: fatigue 14%, anemia 11%, and hypertension 9%.
Based on the Phase 1b/2 clinical trial results, Kim A. Reiss et al. stated: "In pancreatic cancer patients who had not progressed after at least 16 weeks of platinum-based chemotherapy, maintenance therapy with Niraparib + Ipilimumab improved the 6-month progression-free survival rate, while maintenance therapy with Niraparib + Opdivo showed a lesser improvement in the 6-month progression-free survival rate."
Source: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00369-2/fulltext
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4